Salute e Benessere

Digital Access, AI, and 99% e-Prescriptions: Estonia's e-Health Revolution and…

The success of Estonia's e-health system is not only a source of national pride but serves as a valuable model for regions like the GCC, where rapid population growth and an increasing demand for quality healthcare require innovative solutions to manage healthcare resources efficiently and ensure patient satisfaction. The success ofEstonia'se-health system is not only a source of national pride but serves as a valuable model for regions like the GCC, where rapid population growth and an...
PR Newswire
20/12/2024

Avextra Backs Landmark Psilocybin Therapy Study in Palliative Care

News Release Exclusive Industry Role : Avextra is the industry partner in a groundbreaking project focused on psychedelic-assisted therapy for patients in palliative care suffering from depression. Pioneering Research : This multi-centre Phase 2 clinical trial spans four European countries and is sponsored by the University Medical Center Groningen in the Netherlands. Collaborative Effort : 19 partner organizations (universities, companies, foundations, institutes, and patient...
Nasdaq GlobeNewswire
20/12/2024

Global Live Cell Imaging Market: Advances and Growth Prospects

This report covers the global market for live cell imaging, focusing on the tools, software, and services used to study living cells. It breaks down the market and offers insights into products, technologies, major users, and regional trends, Highlights include industry operations, innovations, growth opportunities, and profiles of top companies. This report covers the global market for live cell imaging, focusing on the tools, software, and services used to study living cells. It breaks down...
PR Newswire
20/12/2024

Result of AGM

DXS INTERNATIONAL PLC (AQSE: DXSP)Result of DXS AGM 2024 The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce that all resolutions put to shareholders at the Company's annual general meeting ("AGM") held yesterday were duly passed.All resolutions were passed on a poll and the votes received from shareholders on each resolution put to the AGM...
Nasdaq GlobeNewswire
20/12/2024

Medical Aesthetics Market to Hit US$ 35.32 Billion by 2030 with 12.8% CAGR |…

Browse in-depth TOC on "Medical Aesthetics Market" Browse in-depth TOC on "Medical Aesthetics Market" 253 - Tables 50 - Figures 310 - Pages Based on the product,the medical aesthetics market is categorized into facial aesthetic products, cosmetics implants, skin aesthetic devices, body contouring devices, physician-dispensed cosmeceuticals and skin lighteners, hair removal devices, tattoo removal devices, thread lift products, Physician- dispensed eyelash products and nail...
PR Newswire
20/12/2024

Artificial Intelligence in Oncology Market to Hit US$ 11.52 Billion by 2030 with…

Browse in-depth TOC on "Artificial Intelligence in Oncology Market" Browse in-depth TOC on "Artificial Intelligence in Oncology Market" 250 - Tables 50 - Figures 300 - Pages By application, the drug discovery segment holds significant share in AI in oncology market. This large share is anticipated due to the rising burden of cancer coupled with technological advancements that enhance understanding of disease mechanisms. Further, this segment is classified into drug…
PR Newswire
20/12/2024

Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm…

Renovaro will Establish the GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's certified AI Healthcare Cloud solutions LOS ANGELES, Dec.20, 2024(GLOBE NEWSWIRE) --Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced its subsidiary Renovaro Cube (the “Cube”), a leader in specific AI-driven healthcare solutions, has entered into a strategic collaboration with Nebul ( www.nebul.com ) a leading AI...
Nasdaq GlobeNewswire
20/12/2024

Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer

"We are thrilled to welcome Dr. Xu during this pivotal time in Medicilon's growth," said Dr. Chunlin Chen, Founder and CEO of Medicilon. "Her extensive expertise and global perspective align with our vision of driving innovation and advancing our international presence." "We are thrilled to welcome Dr. Xu during this pivotal time in Medicilon's growth," said Dr.Chunlin Chen, Founder and CEO of Medicilon. "Her extensive expertise and global perspective align…
PR Newswire
20/12/2024

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 20 December 2024– On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.Under…
Nasdaq GlobeNewswire
20/12/2024

SciBase letter from the CEO

We have successfully broadened our presence in the US market with more clinics in new states using Nevisense. We have added individual clinics that diagnose and treat a large number of patients with skin cancer to our target groups, which overall expands SciBase business opportunity. In areas with no reimbursement, we now offer the option of paying directly, a so-called cash-pay model. We are currently testing and evaluating this model in California, the model is proven for other technologies…
PR Newswire
20/12/2024

SciBase publishes prospectus

Publication of the Prospectus Publication of the Prospectus The Prospectus that SciBase has prepared in connection with the Rights Issue has today,December 20, 2024, been approved by the Swedish Financial Supervisory Authority. The Prospectus, containing the full terms and conditions of the Rights Issue, and application forms can be obtained from SciBase and Carnegie and are available on SciBase website ( https://investors.scibase.se/en/mid-disclaimer/107/83 ) and on Carnegie's website...
PR Newswire
20/12/2024

Shaping the Future of Nutraceuticals: Trends, Innovations, and Market Outlook…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=11584039 Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=11584039 Browse in-depth TOC on "Nutraceuticals & dietary supplements Industry Outlook for 2024" 20 – Tables 40 – Figures 80 – Pages Nutraceuticals Industry Developments in 2024 and Predictions for 2025 In 2024, the nutraceuticals & dietary supplements industry witnessed significant growth, driven...
PR Newswire
20/12/2024

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with…

Bagsværd, Denmark, 20 December 2024– Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual components cagrilintide 2.4 mg, semaglutide 2.4 mg and placebo, all administered once-weekly. The trial included 3,417 randomised people with obesity or...
Nasdaq GlobeNewswire
20/12/2024

Rare Disease Consulting: Explore How to Address the Low Prevalence and High…

We recognize the scarcity of published data on rare patient populations, the high unmet needs, and the challenges of inaccurate diagnoses. Over the years, we have built an extensive network of Key Opinion Leaders (KOLs) working in the rare diseases domain. Their invaluable insights enable us to help our clients effectively navigate this challenging landscape. We recognize the scarcity of published data on rare patient populations, the high unmet needs, and the challenges of inaccurate…
PR Newswire
20/12/2024

Idorsia provides update on the exclusive negotiations for the global rights to…

Ad hoc announcement pursuant to Art. 53 LR Company announces delay to the targeted timeline for signing a binding agreementCompany in discussions with bondholders to restructure the company's outstanding debt and extend the operational cash runwayAllschwil, Switzerland – December 20, 2024Idorsia Ltd (SIX: IDIA) today provided an update on the ongoing exclusive negotiations for the global rights to aprocitentan. On November 27, 2024, the company announced that it had entered exclusive...
Nasdaq GlobeNewswire
20/12/2024

Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a…

Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) inpatients aged 4 years and older Follows recent approval from China's National Medical Products Administration (NMPA) Pratteln, Switzerland, December 20, 2024 – Santhera Pharmaceuticals (SIX: SANN) announcesthat the Department of Health of Hong Kong, China, has approved AGAMREE® (vamorolone) for use in patients aged 4 years and older. The approval by the DoH of Hong...
Nasdaq GlobeNewswire
20/12/2024

Coway Listed in the Dow Jones Sustainability Asia Pacific Index for the 12th…

Coway has been on the DJSI Asia Pacific for 12 consecutive years and on the Dow Jones Sustainability Korea Index for 7 years running. It is the only Korean company featured in the DHP Household Durables industry category on the DJSI Asia Pacific Index. Coway has been on the DJSI Asia Pacific for 12 consecutive years and on theDow Jones Sustainability Korea Indexfor 7 years running. It is the only Korean company featured in the DHP Household Durables industry category on the DJSI Asia...
PR Newswire
20/12/2024

A Success Story: Digital Opinion Leader Analysis for Cystic Fibrosis Treatments…

Cystic fibrosis is a life-limiting autosomal recessive genetic disorder that primarily affects the lungs and digestive system, caused by mutations in the CFTR gene. According to DelveInsight's latest Cystic Fibrosis Market and Epidem Forecast Report, the estimated total diagnosed prevalent cases of cystic fibrosis in the 7MM in 2023 were ~68K cases. The UK had the highest number of diagnosed cystic fibrosis cases, with nearly 11K, followed by France with 7.5K and Germany with 7K. In the EU4 and…
PR Newswire
19/12/2024

Innocan Pharma Announces Private Placement of Units

Each Unit will be comprised of: (i) one (1) common share in the capital of the Company (each a "Common Share"); and (ii) one (1) common share purchase warrant (each a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Common Share at a price of [C$0.28] for a period of four (4) years from the date of issuance. Each Unit will be comprised of: (i) one (1) common share in the capital of the Company (each a " Common Share "); and (ii) one (1)…
PR Newswire
19/12/2024

CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 –…

ORION CORPORATIONSTOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS19 DECEMBER 2024 at 22.45 EET CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel Orion corrects the stock exchange release published on 19 December at 19.00 EET. In the original English stock exchange release the first quote by CEO Liisa Hurme differs from the first quote in the Finnish stock exchange release. The quote in the...
Nasdaq GlobeNewswire
19/12/2024

U.S. Food and Drug Administration issues Complete Response Letter for the…

Company announcement – No. 51 / 2024 U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome The FDA concluded that Zealand Pharma's application did not meet the full requirements for substantial evidence to establish the efficacy and safety of the to-be-marketed dose of glepaglutide.Zealand Pharma will continue the dialogue with the FDA to align on the path toward obtaining regulatory...
Nasdaq GlobeNewswire
19/12/2024

Astraveus Secures €7.1M Non-dilutive Funding from the French State

For further information, please contact: Astraveus SASJérémie Laurent, Chief Executive [email protected] For further information, please contact: Astraveus SAS Jérémie Laurent, Chief Executive [email protected] About Astraveus: Astraveus is aParis -based biotech company dedicated to making cell therapies with maximized quality at order-of-magnitude lower cost. With the unique Lakhesys Benchtop Cell Factory™, Astraveus provides bioprocessing innovation...
PR Newswire
19/12/2024

Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko…

ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS 19 DECEMBER 2024 at 19.00 EET Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel Olli Huotari, Senior Vice President responsible for Corporate Functions organization of the Orion Group and Secretary to the Board of Directors of Orion Corporation, and a member of the Executive Management Board of the Orion Group informed earlier of his...
Nasdaq GlobeNewswire
19/12/2024

Presse release: Jean-Paul Kress to join Sanofi's Board of Directors

Jean-Paul Kress to join Sanofi's Board of DirectorsParis, December 19, 2024. Sanofi's Board of Directors is pleased to welcome Jean-Paul Kress as an independent director as of January 1, 2025, replacing Gilles Schnepp who has decided to leave the Board at the end of 2024. Jean-Paul Kress will hold his position for the remainder of Gilles Schnepp's term of office and his appointment will be subject to ratification at the next Ordinary Shareholders' Meeting of Sanofi. Jean-Paul Kress, M...
Nasdaq GlobeNewswire
19/12/2024
Altri  Comunicati